Publications

Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers. by Sader HS, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2011; 69 (2): 223-227

Susceptibility of Klebsiella spp. to colistin and polymyxin B: Results from the SENTRY Antimicrobial Surveillance Program (2006-2009). by Sader HS, Farrell DJ and Jones RN published in Int. J. Antimicrob. Agents. 2011; 37 (2): 174-175

Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). by Pfaller MA, Moet GJ, Messer SA, Jones RN and Castanheira M published in J. Clin. Microbiol. 2011; 49 (1): 396-399

Echinocandin and triazole antifungal susceptibility profiles for Candida spp. Cryptococcus neoformans, and Aspergillus fumigatus: Application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). by Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN published in Diagn. Microbiol. Infect. Dis. 2011; 69 (1): 45-50

Results of the Canadian Ward Surveillance Study (CANWARD) (2007-2009), a journal symposium. by Jones RN published in Diagn. Microbiol. Infect. Dis. 2011; 69 (3): 288

John A. Washington, MD (1936-2010). by Jones RN published in Diagn. Microbiol. Infect. Dis. 2011; 69 (3): 239

Investigation of the potential for mutational resistsance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study by Farrell DJ, Robbins M Rhys-Williams and Love WG published in Antimicrob. Agents Chemother. 2011; 55 (3): 1177-1181

Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates. by Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S and Diekema D published in J. Clin. Microbiol. 2011; 49 (3) : 1110-1112

Triazole and echinocandin wild-type MIC distributions with epidemiological cutoff values for six uncommon species of Candida. by Pfaller MA, Castanheira M, Diekema DJ, Messer SA and Jones RN published in J. Clin. Microbiol. 2011; 49 (11): 3800-3804

Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections. by Fernandez J, Hilliard JJ, Morrow BJ, Melton JL, Flamm RK, Barron AM and Lynch AS published in Antimicrob. Agents Chemother. 2011; 55 (12): 5522-5528

Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY antimicrobial surveillance program. by Farrell DJ, Liverman LC, Biedenbach DJ, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2011; 71 (4): 415-420

Antimicrobial activity of daptomycin tested against Gram-positive strains collected in European hospitals: Results from 7 years of resistance surveillance (2003-2009). by Sader HS, Farrell DJ and Jones RN published in J. Chemother. 2011; 23 (4): 200-206

Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. by Rossolini GM, Dryden MS, Kozlov RS, Quintana A, Flamm RK, Lauffer JM, Lee E, Morrissey I and Group CS published in J. Antimicrob Chemother. 2011; 66 (1): 151-159

Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. by Ross JE, Scangarella-Oman NE, Miller LA, Sader HS and Jones RN published in J. Clin. Microbiol. 2011; 49 (11): 3928-3930

Determination of disk diffusion and MIC quality control guidelines for JNJ-Q2, a novel quinolone. by Ross JE, Liverman LC and Jones RN published in J. Clin. Microbiol. 2011; 49 (8): 3009-3011

In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci. by Farrell DJ, Krause KM and Benton BM published in Diagn. Microbiol. Infect. Dis. 2011; 69 (3): 257-279

In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler’s diarrhea and Clostridium difficile. by Farrrell DJ, Putnam SD Biedenbach DJ, Moro L, Bozzella R, Celasco G and Jones RN published in Antimicrob. Agents Chemother. 2011; 55 (3): 992-996

Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007 by Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN and Mendes RE published in Antimicrob. Agents Chemother. 2011; 55 (3): 1274-1278

Comment on: Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-beta-lactamases. by Castanheira M, Deshpande LM, Mendes RE, Rodriguez-Noriega E, Jones RN, Morfin-Otero, R published in J. Antimicrob. Chemother. 2011; 66 (3): 684-685

Tigecycline Activity Tested against Commonly Isolated Skin and Skin Structure Infection (CSSSI) Pathogens: 2009 USA Surveillance Results, Lead author: Sader HS, presented at 12th annual Western Pacific Congress of Chemotherapy and Infectious Diseases, December 2 – 5, 2010, Singapore

Daptomycin Antimicrobial Activity and Spectrum when Tested against Gram-positive Organisms from Australia and New Zealand (2008-2009), Lead author: Sader HS, presented at 12th annual Western Pacific Congress of Chemotherapy and Infectious Diseases, December 2 – 5, 2010, Singapore

Update on Telavancin Activity Treated Against a Global Collection of Gram-positive Pathogens (2009), Lead author: Jones RN, presented at 12th annual Western Pacific Congress of Chemotherapy and Infectious Diseases, December 2 – 5, 2010, Singapore

Candida Bloodstream Infection (CBI): Comparison of Species Distribution and Antifungal Resistance Patterns in Community Onset (CO) and Nosocomial (NOS) CBI Isolates, Lead author: Jones RN, presented at 12th annual Western Pacific Congress of Chemotherapy and Infectious Diseases, December 2 – 5, 2010, Singapore

Variation of Species Distribution and Antifungal Resistance (R) Among Candida Bloodstream Infection (CBI) Isolates in Four Geographic Regions, Lead author: Jones RN, presented at 12th annual Western Pacific Congress of Chemotherapy and Infectious Diseases, December 2 – 5, 2010, Singapore

Comparative Evaluation of Oritavancin against Gram-positive Pathogens Worldwide (2009), Lead author: Jones RN, presented at 12th annual Western Pacific Congress of Chemotherapy and Infectious Diseases, December 2 – 5, 2010, Singapore

Assessment of Tigecycline Activity against a Worldwide Collection of S. epidermidis, including Strains with Linezolid Resistance Mechanisms, Lead author: Jones RN, presented at 12th annual Western Pacific Congress of Chemotherapy and Infectious Diseases, December 2 – 5, 2010, Singapore

Impact of Revised CLSI and Current EUCAST Carbapenem (CARB) Breakpoints on Enterobacteriaceae (ENT) Susceptibility (S) Rates: Report from SENTRY Program, Lead author: Jones RN, presented at 12th annual Western Pacific Congress of Chemotherapy and Infectious Diseases, December 2 – 5, 2010, Singapore

Impact Assessment of Revised CLSI Cephalosporin Breakpoints (M100-S20, 2010) Using 27,415 Enterobacteriaceae Isolates Tested in the SENTRY Antimicrobial Surveillance Program, Lead author: Rhomberg PR, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Ceftaroline Activity Tested against Common Organisms Causing Skin and Skin-Structure Infections in USA Medical Centers During 2009, Lead author: Sader HS, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Ceftaroline Activity When Tested against Respiratory Tract Infection (RTI) Pathogens Isolated From USA Medical Centers in 2009, Lead author: Sader HS, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Antimicrobial Activity of Ceftaroline Combined with NXL104 When Tested against Enterobacteriaceae Producing Derepressed AmpC β-Lactamase, Lead author: Sader HS, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Worldwide Summary of Ceftobiprole Spectrum and Activity: Potencies against Enterobacteriaceae and Non-Fermentative Gram-Negative Bacilli (59,695 Isolates), Lead author: Farrell DJ, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Worldwide Summary of Ceftobiprole Activity against 108,577 Gram-Positive Pathogens, Lead author: Farrell DJ, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Antimicrobial Activity of a New Fluoroketolide (CEM-101) Tested against Fastidious Gram-Negative Community-Acquired Bacterial Pneumonia (CABP) Pathogens, Lead author: Biedenbach DJ, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Antimicrobial Activity of a New Fluoroketolide (CEM-101) Tested against Streptococcus Pneumoniae Tested by the SENTRY Surveillance Program (2008-2009), Lead author: Biedenbach DJ, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Evaluation of Oritavancin Antimicrobial Activity Tested against Staphylococcus aureus Associated with Skin and Skin-Structure Infections (2008 – 2009), Lead author: Mendes RE, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Activity of Fusidic-Acid Tested against Contemporary Staphylococcus aureus Collected From United States Hospitals, Lead author: Castanheira M, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Epidemiologic Characterization of Carbapenemase-Producing Enterobacteriaceae in India, Lead author: Mendes RE, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Worldwide Summary of Doripenem Spectrum and Activity: Potencies against Non-Fermentative and Fastidious Gram-Negative Pathogens, Lead author: Farrell DJ, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Worldwide Summary of Doripenem Spectrum and Activity: Potencies against Enterobacteriaceae (57,724 Isolates), Lead author: Farrell DJ, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Antimicrobial Susceptibility of Daptomycin and Comparator Agents Tested against Methicillin-Resistant S. aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE): Analysis of a Five-Year Trend in USA Medical Centres (2005-2009), Lead author: Sader HS, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Mutations Associated with Ketolide Resistance in S. Pneumoniae Collected in the 2009 SENTRY Antimicrobial Surveillance Program, Lead author: Farrell DJ, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Experience with Linezolid in Vitro Coverage (% Susceptible) of S. aureus Pneumonia Isolates: Report From the SENTRY Antimicrobial Surveillance Program (1998-2009), Lead author: Jones RN, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Summary of 2009 Oxazolidinone Resistance (R) Surveillance Studies Worldwide (LEADER and ZAAPS Programs), Lead author: Jones RN, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Linezolid Resistance Mechanisms Among Staphylococci and Enterococci Collected From Global Resistance Surveillance Programs, Lead author: Mendes RE, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Tigecycline Activity against Multidrug-Resistant Enterobacteriaceae and Acinetobacter Spp. Isolated in USA Hospitals (2005-2009), Lead author: Sader HS, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Species Distribution and Frequency of Antifungal Resistance (R) Variations Among Candida Bloodstream Infections (BSI) Isolates by Patient Age: Report From the SENTRY Program, Lead author: Pfaller MA, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Candida Bloodstream Infection (CBI): Comparison of Species Distribution and Resistance to Micafungin (MCF) and Azole Antifungal Agents in Intensive Care Unit (ICU) and Non-ICU Settings, Lead author: Pfaller MA, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

JNJ-Q2: a New Fluoroquinolone with Potent In Vitro Activity Against Staphylococcus aureus, Including Methicillin- and Fluoroquinolone-Resistant Strains, Lead author: Farrell DJ, presented at 48th annual Infectious Diseases Society of America (IDSA), October 21 – 24, 2010, Vancouver, Canada

Mechanisms of Resistance and Antimicrobial Susceptibility Profile of Carbapenem-Resistant Acinetobacter baumanii from P.R. China, Lead author: Wang, presented at 50th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2010, Boston, MA